Tohoku University: ALS, treated with human bone marrow-derived Muse cells: administered to model mice
November 2, 2020
reaserch result:
【Overview】
Tohoku University: Professor Mari Dezawa
Okayama University: Professor Koji Abe, Lecturer Toru Yamashita
Collaborative research group:
Human bone marrow-derived Muse cells were intravenously administered to amyotrophic lateral sclerosis (ALS) model mice.
After that, he discovered that it has the effect of suppressing the progression of symptoms in motor function.
Scientific Reports:
These research results were published as a Research Article in the British scientific journal “Scientific Reports” on October 13.
What is ALS:
ALS is an intractable neurological disease in which motor nerve cells in the cerebrospinal cord decrease and motor paralysis continues.
The current situation is that there is no radical treatment.
Human bone marrow-derived Muse cells:
This time, human bone marrow-derived Muse cells were repeatedly administered intravenously.
Migratory to mouse spinal cord (strongly injured lumbar spinal cord),
Differentiates into the cells that make up the spinal cord
Suppresses motor nerve cell loss and hypokinesia,
I was able to confirm the therapeutic effect.
Results of this research:
It is expected to lead to the development of new treatment methods for “saving ALS patients suffering from progressive motor paralysis and respiratory muscle paralysis”.
Press Release / Research Results
Tohoku University-
https://www.tohoku.ac.jp/japanese/2020/11/press20201102-01-als.html
Therapeutic benefit of Muse cells in a mouse model of amyotrophic lateral sclerosis
Toru Yamashita, Yoshihiro Kushida, […]Koji Abe Scientific Reports volume 10, Article number: 17102 (2020)
Cite this article
837 Accesses
51 Altmetric
Abstract
Amyotrophic lateral sclerosis (ALS)
is a fatal neurodegenerative disease characterized by progressive motor neuron loss.
Muse cells
are endogenous reparative pluripotent-like stem cells distributed in various tissues.
They can selectively home to damaged sites after intravenous injection by sensing sphingosine-1-phosphate produced by damaged cells, then exert pleiotropic effects, including tissue protection and spontaneous differentiation into tissue-constituent cells.
In G93A-transgenic ALS mice, intravenous injection of 5.0 × 104 cells
revealed successful homing of human-Muse cells to the lumbar spinal cords, mainly at the pia-mater and underneath white matter, and exhibited glia-like morphology and GFAP expression.
In contrast, such homing or differentiation were not recognized in human mesenchymal stem cells but were instead distributed mainly in the lung.
Relative to the vehicle groups,
the Muse groupsignificantly improved scores in the rotarod, hanging-wire and muscle strength of lower limbs, recovered the number of motor neurons, and alleviated denervation and myofiber atrophy in lower limb muscles.
These results suggest that
Muse cells homed in a lesion site-dependent manner and protected the spinal cord against motor neuron death.
Muse cells might also be a promising cell source for the treatment of ALS patients. Scientific Reports